Early missteps, transparency questions dog U.S. government's remdesivir rollout: reports

When Gilead Sciences scored its groundbreaking FDA emergency use authorization for COVID-19 therapy remdesivir, the company made the unusual move of handing distribution rights to the federal government. But the rollout has gotten off to a rocky start, according to reports.

The medicine—the only one so far to demonstrate positive controlled results against COVID-19—hasn’t gone to certain high-priority hospitals that needed it most, Axios reports. Instead, some remdesivir doses “went to the wrong places,” an unnamed senior Trump administration told the publication.